PMID- 28689085
OWN - NLM
STAT- MEDLINE
DCOM- 20170829
LR  - 20171220
IS  - 1096-0341 (Electronic)
IS  - 0042-6822 (Linking)
VI  - 510
DP  - 2017 Oct
TI  - Identification and characterization of a naturally occurring, efficiently
      cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with
      properties comparable to membrane-bound BG505.
PG  - 22-28
LID - S0042-6822(17)30212-X [pii]
LID - 10.1016/j.virol.2017.07.001 [doi]
AB  - Efficient cleavage of HIV-1 Env gp160 into its constituent subunits correlates
      with selective binding to neutralizing antibodies and are the closest mimetic of 
      native, functional Envs. This was first demonstrated with the clade B Env, JRFL. 
      The correlation between efficient cleavage and selective binding to neutralizing 
      antibodies is the guiding principle for immunogen design for HIV vaccine. We have
      recently reported that Envs 4-2.J41 (clade C) and JRCSF (clade B) are also
      efficiently cleaved and show similar properties. However, an efficiently cleaved,
      membrane-bound clade A Env suitable for genetic vaccination has not been directly
      demonstrated. Here we report that BG505 and a new clade A Env, QB726.70M.ENV.C4
      (or A5) are efficiently cleaved on cell membrane. A5 shows desirable antigenic
      properties comparable with BG505 on cell surface. A5SOSIP in supernatant displays
      majority of bNAb binding epitopes. Thus, both BG505 and A5 Envs can be used in
      DNA prime-protein boost vaccination studies.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Das, Supratik
AU  - Das S
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Boliar, Saikat
AU  - Boliar S
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Samal, Sweety
AU  - Samal S
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Ahmed, Shubbir
AU  - Ahmed S
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Shrivastava, Tripti
AU  - Shrivastava T
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Shukla, Brihaspati N
AU  - Shukla BN
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Goswami, Sandeep
AU  - Goswami S
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Bansal, Manish
AU  - Bansal M
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India.
FAU - Chakrabarti, Bimal K
AU  - Chakrabarti BK
AD  - THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and
      Technology Institute, 3rd Milestone, Faridabad-Gurgaon Expressway, PO box #04,
      Faridabad 121001, Haryana, India; IAVI Neutralizing Antibody Center at TSRI, La
      Jolla, CA, USA. Electronic address: bchakrabarti@iavi.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20170706
PL  - United States
TA  - Virology
JT  - Virology
JID - 0110674
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Epitopes)
RN  - 0 (HIV Antibodies)
RN  - 0 (HIV Antigens)
RN  - 0 (env Gene Products, Human Immunodeficiency Virus)
SB  - IM
MH  - Antibodies, Neutralizing/*immunology
MH  - Cell Membrane/metabolism
MH  - Epitopes/immunology
MH  - HIV Antibodies/*immunology
MH  - HIV Antigens/*immunology/*metabolism
MH  - Protein Binding
MH  - *Proteolysis
MH  - env Gene Products, Human Immunodeficiency Virus/*immunology/*metabolism
OTO - NOTNLM
OT  - *Broadly neutralizing antibodies
OT  - *Clade A
OT  - *Efficiently cleaved
OT  - *Envelope
OT  - *HIV-1
EDAT- 2017/07/10 06:00
MHDA- 2017/08/30 06:00
CRDT- 2017/07/10 06:00
PHST- 2017/02/15 00:00 [received]
PHST- 2017/06/29 00:00 [revised]
PHST- 2017/07/02 00:00 [accepted]
PHST- 2017/07/10 06:00 [pubmed]
PHST- 2017/08/30 06:00 [medline]
PHST- 2017/07/10 06:00 [entrez]
AID - S0042-6822(17)30212-X [pii]
AID - 10.1016/j.virol.2017.07.001 [doi]
PST - ppublish
SO  - Virology. 2017 Oct;510:22-28. doi: 10.1016/j.virol.2017.07.001. Epub 2017 Jul 6.